Eva Moshiro

Ms. Eva Moshiro

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in Parasitologia
Verified
Journal Article
Open access
PDF file
CMCLARA YONA MWASOTA
CLARA YONA MWASOTA
ADAmit Kumar Dey
Amit Kumar Dey
EMEva Moshiro
Eva Moshiro
ALAbel Severin Lupala
Abel Severin Lupala
MMMagreth Macha
Magreth Macha
Leishmaniases are infections caused by Leishmania parasites and transmitted through the bite of infected female Phlebotomus (Old World) and Lutzomyia (New World) sandflies. The disease disproportionately affects marginalized communities with limited healthcare access. With no approved human vaccines available, leishmaniasis treatment and prevention depend heavily on chemotherapeutics that face growing drug resistance challenges alongside toxicity concerns. The development of safe, effective and affordable vaccines against human leishmaniasis remains a global health priority for disease control and elimination, mostly in resource-limited settings. This review synthesizes progress in leishmaniasis vaccine platforms including live-attenuated parasites, whole-killed parasites, DNA, protein subunit, peptide-based and chimeric/multiepitope vaccines and their homogenous and heterogenous efficacy. Live-attenuated and whole-parasite vaccines have been accounted to elicit robust cellular immunity but pose safety risks, particularly in immunocompromised hosts. While both second- and third-generation vaccines exemplified by LEISH-F1/F3 polyproteins, elicit strong Th1-biased T cell responses in preclinical models, their efficacy in humans remains limited. However, the highlighted collective efforts are pivotal in steering the rational development of future research using various formulations for multiple management of leishmaniasis through cross-protection. Furthermore, emerging strategies including mRNA platforms, nanoparticle delivery, reverse vaccinology, and immunoinformatics offer promising avenues for accelerating vaccine discovery and advancing the development of novel and effective human vaccines.

1 January 2025 in Transboundary and Emerging Diseases
Verified
Journal Article
Open access
CMCLARA YONA MWASOTA
CLARA YONA MWASOTA
MMMariam R. Makange
Mariam R. Makange
EMEva Moshiro
Eva Moshiro
Jean HakizimanaJean Hakizimana
Jean Hakizimana
ZMZakile Aliponda Mfumbilwa
Zakile Aliponda Mfumbilwa
Gerald MisinzoGerald Misinzo
Gerald Misinzo
African swine fever (ASF) is a hemorrhagic disease of domestic pigs and wild boars. The ASF virus (ASFV), a sole member of the family Asfarviridae and genus Asfivirus , causes this devastating disease. In sub‐Saharan Africa, ASFV is maintained through three interlinked cycles: the domestic cycle, the pig‐tick cycle, and the sylvatic cycle, which collectively sustain its endemic presence in the region. Interaction between wild and domestic pigs at livestock–wildlife interfaces, particularly in protected areas, poses a significant threat to smallholder farmers. This study aimed to investigate the socioeconomic impact and identify potential risk factors associated with ASF in Serengeti National Park’s (SNP’s) wildlife management area (WMA) in Tanzania. A cross‐sectional study involving 110 domestic pig‐keeping households in the five villages of SNP’s WMA was carried out. A semistructured questionnaire was used to collect data on risk factors and socioeconomic impact associated with ASF from consenting smallholder farmers. Additionally, the observational approach was used to assess pig production’s facilities, behaviors and practices involved in domestic pig production and management. Tissue samples including spleen, lymph nodes, and kidney were also collected from dead domestic pigs belonging to two villages, Nattambiso and Robanda, to confirm the existence of the virus in the study area by using polymerase chain reaction (PCR). Descriptive statistics, univariable, and multivariable logistic analyses were performed to determine risk factors associated with ASF occurrence between October 2021 and April 2022 in the study area. A total of 12 ASF outbreaks affecting 1198 cases that led to 969 domestic pig deaths were reported. The ASFV was confirmed to be positive in all domestic pigs from which tissue samples were collected in the included villages. The case fatality rates (CFRs) from the reported previous ASF incidence varied from 77.5% to 85.2% with an overall CFR of 80.8%. A sum of 163,300,000 Tanzanian Shillings (approximately equivalent to 70,085 USD) loss was recorded in the studied WMA. The major risk factors that correlated with ASF occurrence were encountered ASF previously (odds ratio [OR] = 13.58, 95% confidence interval [CI] = 2.79–87.28), selling pig products with ASF before (OR = 9.43, CI = 1.76–70.02), whilst taking no risk action to prevent loss (OR = 0.14, CI = 0.03–0.63) and swill treatment (OR = 0.10, CI = 0.01–0.54) negatively correlated with ASF. Improving awareness on farm‐level biosecurity, husbandry, and management practices is vital to preventing ASF outbreaks and wildlife spillover, safeguarding livestock health, and promoting economic stability in wildlife–livestock–human interfaces.